Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

CLPT


Top 10 Correlated ETFs

CLPT


Top 10 Correlated Stocks

CLPT


In the News

12:56 03 Oct 2022 CLPT

ClearPoint Neuro: Continuous Great Execution

Revenue growth rebounded strongly due to its acceleration in B&DD and capital equipment and software revenue. The company marks its first milestone with its FDA approval with PTC-AADC, with certainly more to come.

11:20 03 Oct 2022 CLPT

2 Stocks Under $20 to Watch

Here are two interesting companies under $20.

05:11 03 Oct 2022 CLPT

ClearPoint Neuro: Picks & Shovels Galore

Shares have lost 20% of their value since the initial public offering in February of last year. The company is well-positioned as a "picks and shovels" play to pharmaceutical partners addressing neurological indications.

09:04 03 Oct 2022 CLPT

ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Tops Revenue Estimates

ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of 0% and 0.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

07:18 03 Oct 2022 CLPT

ClearPoint Neuro, Inc. (CLPT) CEO Joe Burnett on Q2 2022 Results - Earnings Call Transcript

ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Joe Burnett - Chief Executive Officer Danilo D'Alessandro - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital William Wood - B. Riley Operator Greetings, and welcome to the ClearPoint Neuro Second Quarter 2022 Financial Results Conference Call.

04:12 03 Oct 2022 CLPT

ClearPoint Neuro:  A 'Picks And Shovels' Biotech Company

CLPT has been growing revenues steadily and has a large addressable market. It also has a very strong moat due to the nature of the FDA approval process.

09:14 03 Oct 2022 CLPT

ClearPoint Neuro, Inc. (CLPT) Surges 7.6%: Is This an Indication of Further Gains?

ClearPoint Neuro, Inc. (CLPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

09:25 03 Oct 2022 CLPT

ClearPoint Neuro to Present Investigational Research and Exhibit at the American Society of Gene & Cell Therapy Annual Meeting in Washington, DC

SOLANA BEACH, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced it will present investigational research and exhibit at the 25 th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in Washington, DC.

11:04 03 Oct 2022 CLPT

ClearPoint Neuro, Inc. (CLPT) CEO Joe Burnett on Q1 2022 Results - Earnings Call Transcript

ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Joe Burnett - President & Chief Executive Officer Danilo D'Alessandro - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Marc Weisenberger - B. Riley Securities Operator Greetings and welcome to the ClearPoint Neuro, Inc. First Quarter 2022 Financial Results Conference Call.

04:05 03 Oct 2022 CLPT

ClearPoint Neuro to Announce First Quarter 2022 Results May 11, 2022

SOLANA BEACH, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2022 first quarter on Wednesday, May 11, 2022, after the market close.

Financial details

Company Rating
Neutral
Market Cap
253.7M
Income
-16.39M
Revenue
11.1M
Book val./share
1.79
Cash/share
1.88
Dividend
-
Dividend %
-
Employees
80
Optionable
No
Shortable
Yes
Earnings
07 Nov 2022
P/E
-15.16
Forward P/E
-
PEG
-2.29
P/S
22.39
P/B
5.8
P/C
5.86
P/FCF
-19.22
Quick Ratio
8.84
Current Ratio
10.33
Debt / Equity
0.27
LT Debt / Equity
0.27
-
-
EPS (TTM)
-0.71
EPS next Y
-
EPS next Q
-
EPS this Y
48.79%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-7.21%
Revenue last 5Y
17.17%
Revenue Q/Q
3.36%
EPS Q/Q
5.88%
-
-
-
-
SMA20
-23.08%
SMA50
-23.08%
SMA100
25%
Inst Own
14.32%
Inst Trans
-7.58%
ROA
-27%
ROE
-36%
ROC
-0.29%
Gross Margin
44%
Oper. Margin
-143%
Profit Margin
-148%
Payout
-
Shs Outstand
24.49M
Shs Float
22M
-
-
-
-
Target Price
-
52W Range
7.0-20.55
52W High
-44.88%
52W Low
+57.5%
RSI
39
Rel Volume
0.58
Avg Volume
126.79K
Volume
73.71K
Perf Week
9.05%
Perf Month
-16.73%
Perf Quarter
7.46%
Perf Half Y
-0.85%
-
-
-
-
Beta
1.11266
-
-
Volatility
0.36%, 1.13%
Prev Close
6.42%
Price
11.025
Change
8.3%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
0.950.670.850.810.79
Net income per share
-0.93-0.56-0.42-0.43-0.69
Operating cash flow per share
-0.77-0.42-0.22-0.49-0.61
Free cash flow per share
-0.78-0.43-0.23-0.52-0.62
Cash per share
1.20.280.431.272.61
Book value per share
0.750.140.350.152.35
Tangible book value per share
0.750.140.350.132.35
Share holders equity per share
0.750.140.350.152.35
Interest debt per share
0.750.410.241.460.59
Market cap
20.89M29.97M68.41M374.53M176.03M
Enterprise value
16.52M30.35M64.9M376.1M135.22M
P/E ratio
-2.92-4.86-12.35-55.22-12.22
Price to sales ratio
2.834.086.129.1910.8
POCF ratio
-3.49-6.47-24.01-47.97-13.86
PFCF ratio
-3.47-6.38-22.73-45.18-13.68
P/B Ratio
3.5819.8314.91157.563.61
PTB ratio
3.5819.8314.91157.563.61
EV to sales
2.244.135.7929.328.3
Enterprise value over EBITDA
-2.67-5.98-14.97-78.55-9.2
EV to operating cash flow
-2.76-6.55-22.77-48.18-10.65
EV to free cash flow
-2.74-6.47-21.56-45.37-10.51
Earnings yield
-0.34-0.21-0.08-0.02-0.08
Free cash flow yield
-0.29-0.16-0.04-0.02-0.07
Debt to equity
0.52.30.458.950.24
Debt to assets
0.580.810.620.920.26
Net debt to EBITDA
0.71-0.070.81-0.332.78
Current ratio
2.93.312.717.9613.02
Interest coverage
-7.26-5.35-4.81-4.3113.75
Income quality
0.840.750.511.150.88
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.550.590.380.410.54
Research and developement to revenue
0.380.310.260.370.55
Intangibles to total assets
0000.010
Capex to operating cash flow
00.010.060.060.01
Capex to revenue
0-0.01-0.01-0.04-0.01
Capex to depreciation
-0.23-0.58-0.64-0.88-0.24
Stock based compensation to revenue
0.170.170.070.080.13
Graham number
3.961.321.821.26.07
ROIC
-0.67-0.9-0.57-0.24-0.22
Return on tangible assets
-0.52-0.78-0.46-0.23-0.22
Graham Net
0.4-0.120.06-0.252
Working capital
8.35M4.65M6.55M22.26M57.14M
Tangible asset value
0002.02M0
Net current asset value
4.68M308.86K3.04M-1.68M45.1M
Invested capital
0.842.30.489.120.27
Average receivables
1.42M1.56M1.49M1.88M2.11M
Average payables
529.72K400.46K632.89K300K363.5K
Average inventory
2.78M2.67M3.24M3.24M4.09M
Days sales outstanding
46.9661.2535.4753.5252.33
Days payables outstanding
95.6275.1591.9729.5231.12
Days of inventory on hand
291.39315.93308.56318.65359.9
Receivables turnover
7.775.9610.296.826.97
Payables turnover
3.824.863.9712.3611.73
Inventory turnover
1.251.161.181.151.01
ROE
-1.23-4.08-1.21-2.85-0.3
Capex per share
0-0.01-0.01-0.03-0.01

Quarterly Fundamentals Overview

Last date of statement is 2022-06-30 for Q2

Metric History 2021-06-302021-09-302021-12-312022-03-31 2022-06-30
Revenue per share
0.160.2-0.160.210.22
Net income per share
-0.17-0.18-0.18-0.17-0.18
Operating cash flow per share
-0.17-0.150-0.18-0.21
Free cash flow per share
-0.17-0.150-0.19-0.21
Cash per share
2.862.562.42.11.88
Book value per share
2.231.962.171.931.79
Tangible book value per share
2.211.952.171.921.77
Share holders equity per share
2.231.962.171.931.79
Interest debt per share
0.950.910.510.520.51
Market cap
410.88M399.77M252.7M246.53M313.01M
Enterprise value
369.53M362.29M211.89M209.05M301.56M
P/E ratio
-27.44-25.11-15.23-15.57-18.19
Price to sales ratio
120.3987.4-68.214960.19
POCF ratio
-110.51-121.290-57.75-62.84
PFCF ratio
-111.56-116.860-55.35-61.9
P/B Ratio
8.579.065.185.397.31
PTB ratio
8.579.065.185.397.31
EV to sales
108.2779.21-57.1941.5557.99
Enterprise value over EBITDA
-106.92-98.16-35.72-57.53-75.82
EV to operating cash flow
-99.39-109.920-48.97-60.54
EV to free cash flow
-100.33-105.90-46.94-59.63
Earnings yield
-0.01-0.01-0.02-0.02-0.01
Free cash flow yield
-0.01-0.010-0.02-0.02
Debt to equity
0.410.450.240.250.27
Debt to assets
0.340.360.260.260.29
Net debt to EBITDA
11.9710.156.8810.312.88
Current ratio
15.6214.1713.0214.610.33
Interest coverage
-14.2-15.982.23-36.45-46.2
Income quality
0.990.8301.081.16
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.580.53-0.720.540.58
Research and developement to revenue
0.620.57-0.720.50.44
Intangibles to total assets
0000.010.01
Capex to operating cash flow
00.0400.040.02
Capex to revenue
0-0.030-0.04-0.01
Capex to depreciation
0-2.450-0.84-0.32
Stock based compensation to revenue
0.070.1300.180.17
Graham number
2.952.7932.692.68
ROIC
-0.05-0.06-0.07-0.07-0.08
Return on tangible assets
-0.05-0.06-0.06-0.06-0.07
Graham Net
1.891.641.841.611.4
Working capital
64.12M60.41M57.14M54.04M51.16M
Tangible asset value
47.66M43.83M045.38M42.5M
Net current asset value
44.15M40.41M45.1M41.98M39.22M
Invested capital
0.420.460.270.270.28
Average receivables
2.33M2.4M2.29M2.24M2.8M
Average payables
1.11M871K696K965K1.28M
Average inventory
4.65M4.84M5.34M5.73M6.19M
Days sales outstanding
63.4750.35-56.7740.1357.95
Days payables outstanding
100.3447.0639.0948.6673.74
Days of inventory on hand
286.51238.81452.11289.01307.52
Receivables turnover
1.421.79-1.592.241.55
Payables turnover
0.91.912.31.851.22
Inventory turnover
0.310.380.20.310.29
ROE
-0.08-0.09-0.09-0.09-0.1
Capex per share
0-0.010-0.010

Frequently Asked Questions

What is ClearPoint Neuro, Inc. stock symbol ?

ClearPoint Neuro, Inc. is a US stock , located in Irvine of California and trading under the symbol CLPT

What is ClearPoint Neuro, Inc. stock quote today ?

ClearPoint Neuro, Inc. stock price is $11.025 today.

Is ClearPoint Neuro, Inc. stock public?

Yes, ClearPoint Neuro, Inc. is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap